基于方案的2019冠状病毒病管理清单

IF 1.5 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL
Behjat Taheri, Amirhossein Akhavan Sigari, Leili Kamali, Ahmad Zarei, Firouzeh Moeinzadeh, Marzieh Salimi Bani, Saeed Abbasi
{"title":"基于方案的2019冠状病毒病管理清单","authors":"Behjat Taheri, Amirhossein Akhavan Sigari, Leili Kamali, Ahmad Zarei, Firouzeh Moeinzadeh, Marzieh Salimi Bani, Saeed Abbasi","doi":"10.4103/jrms.jrms_169_22","DOIUrl":null,"url":null,"abstract":"| 2023 | 1 been dedicated to corticosteroid treatment. Usually, 8 mg of dexamethasone is given daily intravenously for up to 10 days. Higher doses can cause adverse events such as osteoporosis and elevated blood glucose levels[2] 4. Cytokine storm: This section is divided into two sections: diagnostic criteria and treatment. When cytokine storm clinical data are met, the syndrome is confirmed with laboratory testing. Management is l imited to dexamethasone and methylprednisolone in different doses. Tocilizumab is also mentioned at the end of the checklist under the subheading “miscellaneous treatments”[3] 5. Anticoagulation and gastrointestinal care: Based on national protocols, we provide these two sections for prophylactic measures. Prophylactic anticoagulation based on patient body mass index and hospitalization status is provided. Acid blocking agents are also given based on patient risk factors and hospitalization status[4] 6. Antibiotics and antiviral therapy: Based on designated criteria such as refractory fever, decreased consciousness, and oxygen saturation, as well as the physician’s expert opinion, antiviral therapy (remdesivir) and antibiotic treatment are initiated.","PeriodicalId":50062,"journal":{"name":"Journal of Research in Medical Sciences","volume":"28 ","pages":"9"},"PeriodicalIF":1.5000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/12/85/JRMS-28-9.PMC10039103.pdf","citationCount":"0","resultStr":"{\"title\":\"A protocol-based checklist for the management of coronavirus disease 2019.\",\"authors\":\"Behjat Taheri, Amirhossein Akhavan Sigari, Leili Kamali, Ahmad Zarei, Firouzeh Moeinzadeh, Marzieh Salimi Bani, Saeed Abbasi\",\"doi\":\"10.4103/jrms.jrms_169_22\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"| 2023 | 1 been dedicated to corticosteroid treatment. Usually, 8 mg of dexamethasone is given daily intravenously for up to 10 days. Higher doses can cause adverse events such as osteoporosis and elevated blood glucose levels[2] 4. Cytokine storm: This section is divided into two sections: diagnostic criteria and treatment. When cytokine storm clinical data are met, the syndrome is confirmed with laboratory testing. Management is l imited to dexamethasone and methylprednisolone in different doses. Tocilizumab is also mentioned at the end of the checklist under the subheading “miscellaneous treatments”[3] 5. Anticoagulation and gastrointestinal care: Based on national protocols, we provide these two sections for prophylactic measures. Prophylactic anticoagulation based on patient body mass index and hospitalization status is provided. Acid blocking agents are also given based on patient risk factors and hospitalization status[4] 6. Antibiotics and antiviral therapy: Based on designated criteria such as refractory fever, decreased consciousness, and oxygen saturation, as well as the physician’s expert opinion, antiviral therapy (remdesivir) and antibiotic treatment are initiated.\",\"PeriodicalId\":50062,\"journal\":{\"name\":\"Journal of Research in Medical Sciences\",\"volume\":\"28 \",\"pages\":\"9\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/12/85/JRMS-28-9.PMC10039103.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Research in Medical Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4103/jrms.jrms_169_22\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Research in Medical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/jrms.jrms_169_22","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
A protocol-based checklist for the management of coronavirus disease 2019.
| 2023 | 1 been dedicated to corticosteroid treatment. Usually, 8 mg of dexamethasone is given daily intravenously for up to 10 days. Higher doses can cause adverse events such as osteoporosis and elevated blood glucose levels[2] 4. Cytokine storm: This section is divided into two sections: diagnostic criteria and treatment. When cytokine storm clinical data are met, the syndrome is confirmed with laboratory testing. Management is l imited to dexamethasone and methylprednisolone in different doses. Tocilizumab is also mentioned at the end of the checklist under the subheading “miscellaneous treatments”[3] 5. Anticoagulation and gastrointestinal care: Based on national protocols, we provide these two sections for prophylactic measures. Prophylactic anticoagulation based on patient body mass index and hospitalization status is provided. Acid blocking agents are also given based on patient risk factors and hospitalization status[4] 6. Antibiotics and antiviral therapy: Based on designated criteria such as refractory fever, decreased consciousness, and oxygen saturation, as well as the physician’s expert opinion, antiviral therapy (remdesivir) and antibiotic treatment are initiated.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Research in Medical Sciences
Journal of Research in Medical Sciences MEDICINE, GENERAL & INTERNAL-
CiteScore
2.60
自引率
6.20%
发文量
75
审稿时长
3-6 weeks
期刊介绍: Journal of Research in Medical Sciences, a publication of Isfahan University of Medical Sciences, is a peer-reviewed online continuous journal with print on demand compilation of issues published. The journal’s full text is available online at http://www.jmsjournal.net. The journal allows free access (Open Access) to its contents and permits authors to self-archive final accepted version of the articles on any OAI-compliant institutional / subject-based repository.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信